PMC

Figure 1. The CCR5 antagonist Maraviroc inhibits lung metastases in vivo. MDA-MB-231 cells expressing luciferase fused to an enhanced variant of the green-fluorescent protein (Luc2-eGFP) were injected into the tail vein of NOD/SCID mice and the bioluminescent signal was quantified weekly in vivo. Representative images of mice receiving vehicle or 8 mg/Kg Maraviroc (every 12 h) are shown in (A) Quantitative data on bioluminescence imaging (means ± SEM, n = 6) are reported in panel (B) (control mice = red line; treated mice = blue line). Statistical comparisons (*p = 0.048) were by means of Student's t-tests coupled to Welch’s correction for heterogeneous variances. (C) The presence of pulmonary tumors and the differences between experimental groups were corroborated by ex vivo imaging (left panels) and India ink staining (right panels).